Dupixent for chronic hives in NYC

The current Dupixent label includes adults and children age 2 and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.

The allergy clinician confirms CSU rather than another form of hives, reviews prior treatment and age-appropriate dosing, and plans injection training, coverage, specialty-pharmacy delivery, and follow-up.

Acute swelling and breathing symptoms need urgent action

Call 911 for tongue or throat swelling, severe breathing difficulty, fainting, or a rapidly progressing reaction. Dupixent is not emergency treatment for an acute allergic reaction.

What must be confirmed for Dupixent in CSU

The indication requires confirmed CSU with symptoms that persist despite H1 antihistamine treatment.

The hives pattern is chronic and spontaneous

The clinician confirms recurrent wheals, angioedema, or both for more than six weeks without a consistent external trigger.

H1 antihistamine treatment has been reviewed

The visit documents the medication, dose, adherence, response, side effects, and clinician-directed optimization.

Age, weight, and caregiver needs are clear

Pediatric dosing and the person responsible for injections vary by age and weight under the current label.

What to expect from evaluation through follow-up

The order and timing vary by diagnosis, prescribing responsibility, coverage, medication delivery, and the confirmed care site.

1. Confirm CSU

Review duration, photographs, triggers, swelling, lesion behavior, associated symptoms, and findings that suggest another type of urticaria or diagnosis.

2. Document prior treatment

Review H1 antihistamine treatment, other medicines, prior biologics, response, side effects, and reasons for considering Dupixent.

3. Set the dose and training plan

The prescriber applies the current age- and weight-specific label and determines whether a patient or caregiver will inject after training.

4. Coordinate access

Confirm authorization, expected cost, pharmacy route, eligible support resources, medication delivery, and the accepted training or administration site.

5. Track response and safety

Follow wheals, itch, swelling, sleep, daily function, injection technique, adverse effects, and whether the diagnosis or treatment plan needs reconsideration.

The 2026 CSU label update matters

The current DailyMed label was updated April 22, 2026 and expanded pediatric CSU use. The final prescription still depends on a clinician's diagnosis, age- and weight-specific dosing, safety review, and payer rules.

Dupixent is labeled for CSU in adults and pediatric patients age 2 and older who remain symptomatic despite H1 antihistamine treatment.
Dupixent is not indicated for other forms of urticaria. Acute hives, inducible hives, medication reactions, and other causes need a different pathway.
The labeled dose and schedule vary by age and body weight. Do not copy a dose from another condition or another patient.
Patients or caregivers may inject after proper training and under the age-specific supervision rules in the current label.

Coverage, outside orders, and specialty-pharmacy delivery

Nao can coordinate these steps when the clinical program and receiving site approve the plan. Coverage, assistance, delivery time, and administration are never guaranteed.

Outside-order review

A valid order is reviewed with the diagnosis, dose, records, responsible prescriber, adverse-event plan, refill responsibility, and follow-up. Acceptance is not automatic.

Benefits and authorization

The care team can review the pharmacy or medical benefit, documentation, prior authorization, appeal path, expected patient cost, and eligible support resources.

Confirmed delivery and appointment

A specialty pharmacy may send patient-specific medication only after Nao provides the accepted clinic and delivery instructions. Administration is scheduled after receipt and safety confirmation.

Dupixent CSU safety and follow-up

Report a clinically significant hypersensitivity reaction and seek emergency care for severe symptoms.
Report persistent or worsening eye symptoms, new joint symptoms, or another concerning change after treatment starts.
Review vaccines and parasitic-infection risk with the prescriber before treatment.
Do not ship medication or arrive for injection support until the receiving clinic confirms the plan.

Review Nao Medical's urgent and emergency care guidance. Call 911 for a life-threatening emergency.

Clinics available for evaluation booking

The specialty route offers evaluation booking across these 11 clinics through the PCP NP visit type. Appointment times vary. An evaluation location is not automatically an administration location. Nao does not promise on-hand medication or same-day injection. The care team confirms the eligible administration site separately for each patient and product.